FDA Approves Merck ’s Keytruda (pembrolizumab) in Combination With Padcev (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

RAHWAY, N.J.--(BUSINESS WIRE) April 3, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news